- HOME
- 홈페이지 이용안내
논문 기본정보
全合成アントラサイクリン系抗癌 #34220; #22633;酸アムルビシン #65288;カルセド? #65289;の抗腫瘍作用
논문 개요
| 기관명 | NDSL |
|---|---|
| 저널명 | 日本藥理學雜誌 = Folia pharmacologica Japonica |
| ISSN | 0015-5691,1347-8397 |
| ISBN |
논문저자 및 소속기관 정보
| 저자(한글) | 花田 充治,野口 俊弘,村山 隆夫 |
|---|---|
| 저자(영문) | |
| 소속기관 | |
| 소속기관(영문) | |
| 출판인 | |
| 간행물 번호 | |
| 발행연도 | 2003-01-01 |
| 초록 | Amrubicin is a completely synthetic anthracycline derivative. In contrast, however, the anthracyclines used clinically thus far have been produced by fermentation or semisynthesis. Amrubicin is structurally distinguishable from other anthracyclines by the amino group at the 9-position and its unique sugar moiety. Amrubicinol, the C-13 hydroxy- metabolite of amrubicin, is associated with a 5 to 200 times greater cytotoxicity than amrubicin. Amrubicin exhibited superior in vivo antitumor activity to doxorubicin in the human tumor xenograft model. Using this model, the level of amrubicinol (active metabolite) was shown to be higher than that of doxorubicin in tumor tissues, but lower in normal tissues. These results suggest potent therapeutic activity for amrubicin because of the selective distribution of its highly active metabolite, amrubicinol, in tumors. These anti-tumor effects of amrubicin are considered to be induced by DNA topoisomeraseII inhibition. In clinical studies, amrubicin has demonstrated potent single agent activity as compared to a standard regimen in untreated patients with extensive small cell lung cancer. Its major toxicity was myelosuppression (especially neutropenia). |
| 원문URL | http://click.ndsl.kr/servlet/OpenAPIDetailView?keyValue=03553784&target=NART&cn=NART18620032 |
| 첨부파일 |
추가정보
| 과학기술표준분류 | |
|---|---|
| ICT 기술분류 | |
| DDC 분류 | |
| 주제어 (키워드) | #22633,酸アムルビシン,カルセド,DNAトポイソメラ #12540,ゼII阻害 #34220,. 肺癌, #24746,性リンパ腫,amrubicin hydrochloride,calsed,DNA topoisomerase II inhibitor,lung cancer,malignant lymphoma |